---
id: tmp-smx-adverse-effects_176
category: antimicrobials
tags: [tmp-smx, adverse-effects, hypersensitivity, hyperkalemia, sjs-ten]
deck: Infectious Diseases
created: 2025-11-11
modified: 2025-11-11
---

## TMP-SMX - Adverse Effects

**Q:** What are the major adverse effects of TMP-SMX including hypersensitivity reactions, hematologic toxicity, and metabolic derangements?

**A:**

## HYPERSENSITIVITY REACTIONS

**Mnemonic: "RASH-SJS-TEN-DRESS"**

### **Mild Cutaneous Reactions (Most Common):**

**Maculopapular Rash:**
- **Incidence:** 3-5% (general population)
- **HIV patients:** **30-50%** (much higher risk)
- **Onset:** 7-14 days (delayed hypersensitivity)
- **Management:** Consider continuing if mild, otherwise discontinue

**Key Point:** **HIV patients = 30-50% rash risk** (10x higher than general population)

---

### **Severe Cutaneous Adverse Reactions (SCAR):**

**Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN):**
- **Incidence:** 1 in 1,000 to 1 in 10,000
- **Mortality:** SJS = 5-10% | TEN = 30-50%
- **Onset:** 7-21 days (usually 1-3 weeks)
- **Presentation:**
  - **Fever** + **mucosal involvement** (mouth, eyes, genitals - >2 sites)
  - **Skin detachment** (SJS <10% BSA | TEN >30% BSA)
  - **Positive Nikolsky sign** (skin sloughs with pressure)
- **Risk factors:** HIV, slow acetylators, HLA-B*15:02 (Asian populations)

**DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms):**
- **Onset:** 2-6 weeks (later than SJS/TEN)
- **Features:** **Fever + rash + eosinophilia + organ involvement** (liver, kidney)
- **Mortality:** 5-10%

**Key Point:** **SJS/TEN = mucosal involvement + skin detachment** | **HIV = highest risk**

---

## HEMATOLOGIC TOXICITY

**Mnemonic: "BONE-MARROW-SUPPRESSION"**

**Mechanism:** **Folate antagonism** → impaired DNA synthesis

### **Megaloblastic Anemia:**
- **Mechanism:** TMP inhibits DHFR → blocks folate metabolism
- **Risk factors:** Folate deficiency, malnutrition, alcoholism, HIV
- **Labs:** **High MCV** (>100 fL), hypersegmented neutrophils
- **Prevention:** **Leucovorin (folinic acid)** supplementation (does NOT reduce drug efficacy)

### **Thrombocytopenia:**
- **Incidence:** 1-5%
- **Onset:** 7-14 days
- **Mechanism:** Immune-mediated platelet destruction
- **Severity:** Can be severe (<20,000/μL)

### **Neutropenia:**
- **Incidence:** 1-5%
- **Mechanism:** Bone marrow suppression (folate antagonism)
- **Risk factors:** Prolonged therapy (>2 weeks), high-dose (PCP treatment)

**Key Point:** **Megaloblastic anemia = folate antagonism** | **Prevent with leucovorin**

---

## METABOLIC DERANGEMENTS

**Mnemonic: "HYPERKALEMIA-HYPONATREMIA-AZOTEMIA"**

### **Hyperkalemia (Most Serious Metabolic Effect):**
- **Mechanism:** **TMP blocks ENaC (epithelial sodium channel)** in collecting duct
  - Acts like **amiloride** (potassium-sparing diuretic)
  - **Inhibits K+ secretion** → hyperkalemia
- **Incidence:** 20-30% (mild elevation) | 5-10% (clinically significant >5.5 mEq/L)
- **Risk factors:**
  - **Renal insufficiency** (GFR <30)
  - **Older age** (>65 years)
  - **Concomitant K+-sparing diuretics** (spironolactone, amiloride)
  - **ACE inhibitors / ARBs**
  - **High-dose TMP-SMX** (PCP treatment)
- **Onset:** 5-7 days
- **Monitoring:** Check K+ at baseline and day 5-7 (especially if high risk)

**Key Point:** **TMP = amiloride-like effect** → blocks K+ secretion → hyperkalemia (check K+ day 5-7)

---

### **Hyponatremia:**
- **Mechanism:** SIADH (syndrome of inappropriate ADH secretion)
- **Incidence:** 5-10%
- **Risk factors:** Elderly, HIV, volume depletion

### **Azotemia (Elevated Creatinine):**
- **Mechanism:** **TMP inhibits tubular creatinine secretion** (NOT true renal injury)
  - **Blocks OCT2 transporter** → creatinine accumulates
  - **GFR unchanged** (no actual renal damage)
- **Effect:** **Cr increases by 0.3-0.5 mg/dL** (usually within 5-7 days)
- **Reversible:** Cr normalizes after discontinuation

**Key Point:** **TMP → false Cr elevation** (blocks creatinine secretion, GFR unchanged)

---

## HEPATOTOXICITY

**Cholestatic Hepatitis:**
- **Incidence:** 1-5%
- **Onset:** 1-3 weeks
- **Labs:** **Elevated ALP, bilirubin** > AST/ALT (cholestatic pattern)
- **Reversible:** Resolves after discontinuation

**Key Point:** **Cholestatic hepatitis** (elevated ALP/bili) - reversible

---

## RENAL TOXICITY

**Acute Interstitial Nephritis (AIN):**
- **Incidence:** 1-2%
- **Onset:** 7-14 days
- **Presentation:** **Fever, rash, eosinophilia, AKI**
- **Urinalysis:** **WBC casts, eosinophiluria**
- **Management:** Discontinue TMP-SMX, consider steroids if severe

**Crystalluria / Nephrolithiasis:**
- **Mechanism:** **Sulfonamide crystals** precipitate in acidic urine
- **Risk factors:** Dehydration, acidic urine (pH <6)
- **Prevention:** **Hydration** + urine alkalinization (if needed)

**Key Point:** **AIN = fever, rash, eosinophils, AKI** | **Crystalluria = dehydration + acidic urine**

---

## DRUG INTERACTIONS

**Mnemonic: "WARFARIN-METHOTREXATE-SULFONYLUREAS"**

### **Warfarin:**
- **Effect:** **Potentiates warfarin** → increased INR
- **Mechanism:** TMP inhibits CYP2C9 (warfarin metabolism)
- **Management:** Monitor INR closely, reduce warfarin dose if needed

### **Methotrexate:**
- **Effect:** **Increased methotrexate toxicity** (both are DHFR inhibitors)
- **Mechanism:** Additive folate antagonism
- **Risk:** Severe bone marrow suppression
- **Management:** Avoid concomitant use if possible, give leucovorin if unavoidable

### **Sulfonylureas (Glyburide, Glipizide):**
- **Effect:** **Hypoglycemia** (TMP displaces sulfonylureas from protein binding)
- **Management:** Monitor glucose closely

### **ACE Inhibitors / ARBs:**
- **Effect:** **Increased hyperkalemia risk** (additive K+ retention)
- **Management:** Monitor K+ closely (day 5-7)

**Key Point:** **Warfarin = increased INR** | **Methotrexate = severe toxicity** (both DHFR inhibitors)

---

## CONTRAINDICATIONS

**Absolute:**
- **Sulfa allergy** (anaphylaxis, SJS/TEN history)
- **Pregnancy - first trimester** (folate antagonism → neural tube defects)
- **Pregnancy - third trimester** (kernicterus risk in neonate)
- **Infants <2 months** (kernicterus risk - competes for bilirubin binding)
- **Severe hepatic or renal failure** (increased toxicity risk)
- **Megaloblastic anemia due to folate deficiency** (worsens anemia)

**Relative:**
- **G6PD deficiency** (hemolysis risk with sulfonamides)
- **Porphyria** (may precipitate acute attack)

**Key Point:** **Avoid first/third trimester** (neural tube defects, kernicterus) | **Avoid infants <2 months** (kernicterus)

---

## DESENSITIZATION PROTOCOL

**Indication:** HIV patients with PCP who require TMP-SMX but have prior mild rash (NOT for SJS/TEN)

**Gradual Dose Escalation (Oral):**
- **Day 1:** 1/10 of target dose
- **Day 2:** 1/4 of target dose
- **Day 3:** 1/2 of target dose
- **Day 4:** Full dose

**Success Rate:** 70-80% (can tolerate full dose after desensitization)

**Key Point:** **Desensitization = gradual dose escalation** (70-80% success, NOT for SJS/TEN)

---

**Clinical Pearls:**
- **HIV patients = 30-50% rash risk** (10x higher than general population)
- **SJS/TEN = mucosal involvement + skin detachment** | **Mortality 30-50% (TEN)**
- **Megaloblastic anemia = folate antagonism** | **Prevent with leucovorin**
- **TMP = amiloride-like effect** → hyperkalemia (check K+ day 5-7)
- **Risk factors for hyperkalemia:** Renal insufficiency, ACE-I/ARB, age >65, K+-sparing diuretics
- **TMP → false Cr elevation** (blocks creatinine secretion, GFR unchanged)
- **Warfarin = increased INR** (TMP inhibits CYP2C9)
- **Methotrexate = severe toxicity** (both DHFR inhibitors - avoid combination)
- **Avoid first/third trimester** (neural tube defects, kernicterus)
- **AIN = fever, rash, eosinophils, AKI** (WBC casts, eosinophiluria)
- **Desensitization possible** (70-80% success, NOT for SJS/TEN)

**Media:**

**Additional Resources:**
- **UpToDate:** TMP-SMX adverse effects
- **IBCC:** https://emcrit.org/ibcc/tmp-smx/
- **FDA Safety Communication:** TMP-SMX hyperkalemia

**Sources:** [UpToDate TMP-SMX], [IBCC TMP-SMX], [FDA Safety Communication]
